


**Murine embryonic stem cells as a route towards exploring
host-pathogen interactions**

**By
Raffaella Rossi**

This dissertation is submitted for the degree of Doctor of Philosophy

September 2008



**Clare Hall College
Cambridge University**



Sanger Institute

Abstract

In the last 20 years embryonic stem (ES) cells have emerged as a new hope for future therapeutic solutions for chronic human diseases such as Alzheimer's, Parkinson's, cancer and cardiovascular disease. They may also pave the way for pharmaceutical drug discovery, minimizing the reliance on animal models. In this study the potential of murine embryonic stem cell technology to probe host-pathogen interactions and infectious diseases is investigated, focusing on the pathogens *Shigella* and *Salmonella* that are able to establish complicated lifestyles within mammalian cells. Murine ES cells were infected independently with *Shigella flexneri* and *Salmonella Typhimurium* and characterized by flow cytometry, microbiology and microscopic observations. It was observed that these pathogens could enter and survive within ES cells in a manner that resembled their interactions with terminally differentiated cells growing in culture. Consequently there is evidence that substantiates the proposal that mouse ES cells could be comparably infected by these bacteria since they also occupied similar intracellular niches. Once the infection protocol was established, the mRNA expression profile of ES cells during infection was investigated, using Affymetrix mouse arrays. The data produced was analyzed by three separate programmes: Bioconductor, GeneSpring and ASCA and they identified a weak immune response. This highlighted the fact that ES cells maintain strict controls on gene expression and that bacterial infection does not induce a characteristic immune response as in specialized cells. Consequently, the potential of ES cells to be differentiated into specific antigen presenting cells like dendritic cell was explored. After differentiation of the ES cells into dendritic cells and their characterization by flow cytometry, the resulting cells were infected with *S. Typhimurium* and purified by FACs sorting in order to perform mRNA expression profiling utilizing Illumina arrays. The expression pattern of surface antigenic markers and the ability of these cells to present antigen and secrete cytokines was also analyzed. The microarray data analysis, cell marker studies and cytokine production profiles emphasized a clear immunological response to bacterial infection in the murine ES derived dendritic cells (esDC). This is the first study of this type performed and further analysis may help to understand both the cell differentiation process and ES cell behavior during infection. In addition, this study revealed the flexibility and the applicability of ES cells as a new *in vitro* model for infectious disease research.

Acknowledgements

Firstly, I would like to thank Professor Gordon Dougan for giving me the opportunity to complete my Ph.D. in his laboratory at the Sanger Institute, for his support and enthusiasm.

I would also like to thank Dr. Hale, Dr. Yu and Dr. Petrovska for their precious experienced tips, to Dr. Lefebvre, Dr. Andrew, Dr. Conesa and Dr. Lynn for helping me with the microarray analyses. A special thank goes to Chris, Linda and Angela for the constructive discussions, suggestions and critical reading of the thesis and to Kat for final proofreading of the thesis and constructive suggestions.

I would like to thank all the members of teams 15 and 100 for keeping the spirit up, the camping trips, the dragon race and evening drinks. I am thankful also to my thesis committee members for suggestions and support. A special thanks goes to all the wonderful people I met during this experience that contributed to making it unforgettable!

A special thank goes to Jim who helped me all through this experience and never doubted that I could do it. His support and positive thinking have been essential.

Un ringraziamento e un pensiero particolare va alla mia famiglia che in questi anni mi ha sostenuto e incoraggiato da lontano e a volte di persona. Il loro supporto e continua fiducia mi hanno aiutato enormemente a raggiungere questo obiettivo.

I would like to dedicate this thesis to my family.

Declaration

I declare that this dissertation is the result of my own work and includes nothing which is the outcome of work done in collaboration, except where specifically indicated in the text.

The gentamicin assays employing wild type *Shigella* were performed in collaboration with Dr. Jun Yu. Guidance with the bone marrow extraction and bone marrow dendritic cells differentiation was provided by Dr. Petrovska. The microarray analyses using Bioconductor were performed by Dr. Lefebvre, Dr. Andrews from the Wellcome Trust Sanger Institute, and the analysis using ASCA was performed by Dr. Conesa from the Centro de Investigación Príncipe Felipe. Synthesis of cDNA, cRNA and hybridizations on Illumina arrays was performed by Peter Ellis from the microarray facility at Wellcome Trust Sanger Institute. Electron microscopy pictures were taken by David Goulding the microscope officer at the Wellcome Trust Sanger Institute.

All the other techniques including tissue cultures, FACS analyses, confocal characterization, Affymetrix hybridization, GeneSpring analysis, RT-PCR, statistical analysis and optimization of invasion protocols were performed by the author.

Raffaella Rossi

September, 2008

Paper

Interaction of Enteric bacteria Pathogens with Murine Embryonic Stem Cells

Jun Yu*, **Raffaella Rossi***, Christine Hale, David Goulding and Gordon Dougan.

Infection and Immunity, Feb. 2009.

Doi:10.1128/IAI.01003-08

Index

1	Introduction.....	19
1.1	General Introduction.....	19
1.2	Host-pathogen interaction.....	21
1.2.1	Infectious diseases today	21
1.2.2	Methods to study host-pathogen interactions	23
1.2.2.1	Historical.....	23
1.2.2.2	The use of genetics	24
1.2.2.3	The use of cell culture.....	25
1.3	<i>Shigella</i>	27
1.3.1	Bacteria and disease.....	27
1.3.2	Mechanism of host invasion	28
1.3.2.1	Type III secretion.....	28
1.3.2.2	Intracellular lifestyle	29
1.4	<i>Salmonella</i>	32
1.4.1	History	32
1.4.2	Bacteria and disease.....	32
1.4.3	Type Three Secretion Systems	33
1.4.4	Mechanism of host invasion	35
1.5	Embryonic stem cells.....	37
1.5.1	History	37
1.5.2	Murine ES cells.....	37
1.5.3	Differentiating ES cells.....	38
1.5.4	ES cell mutants and KO mice	40
1.6	Dendritic Cells	43
1.6.1	What are they?	43
1.6.2	Antigen interaction	44
1.6.3	Antigen processing and presentation by DCs	47
1.6.4	Interaction of DCs with <i>Salmonella</i>	49
1.7	Microarray technology.....	50
1.7.1	Overview.....	50
1.7.2	Microarrays and gene expression	51

1.7.3	Other uses of microarrays	52
1.7.4	Analysis tools.....	53
1.8	Aims of the thesis	55
2	Materials and Methods.....	56
2.1	Materials	56
2.1.1	Bacteria	56
2.1.2	Cell lines	56
2.1.3	Tissue culture.....	57
2.1.4	<i>In vitro</i> infection	58
2.1.5	Flow cytometry	58
2.1.6	Bone marrow extraction materials.....	59
2.1.7	Cytokines	60
2.1.8	Confocal microscopy	60
2.1.9	Antigen presentation assay	60
2.1.10	RNA extraction	61
2.1.11	RNA quantification and quality.....	61
2.1.12	Real Time RT-PCR.....	61
2.1.13	Microarrays.....	62
2.1.13.1	Affymetrix array	62
2.1.13.2	Illumina array.....	62
2.1.13.3	Microarray analysis tools.....	63
2.2	Methods	64
2.2.1	<i>In vitro</i> culture of mouse ES cell lines.....	64
2.2.2	<i>In vitro</i> culture of Hep2 and J774A.1 and MF2.2d9.....	64
2.2.3	Bacterial strains.....	65
2.2.3.1	Invasion assay using <i>Shigella flexneri</i>	65
2.2.3.2	Invasion assay with <i>S. Typhimurium</i>	66
2.2.3.3	Viable count analysis or Gentamicin invasion assay	67
2.2.4	Flow Cytometric Analyses.....	67
2.2.4.1	<i>In vitro</i> bacterial infection (Gentamicin invasion assay)	67
2.2.4.2	Murine ES cells characterization	67
2.2.4.3	EsDC and BMDC surface markers	68
2.2.4.4	Cell Sorting	68
2.2.4.5	Cytometric Bead Array (CBA) Analysis	68

2.2.5	Immunofluorescence labeling.....	69
2.2.5.1	Murine ES cells infected by <i>Shigella flexneri</i> or <i>S. Typhimurium</i>	69
2.2.5.2	EsDC immunofluorescence labeling	69
2.2.6	Total RNA extraction, quantification and Bioanalyzer analysis	70
2.2.7	Affymetrix Microarray	70
2.2.8	Real Time RT-PCR.....	71
2.2.9	Dendritic cell differentiation.....	72
2.2.9.1	Differentiation of murine ES cells into dendritic cells	72
2.2.9.2	Bone marrow extraction and dendritic cells differentiation	72
2.2.9.3	Antigen presentation assay	73
2.2.9.4	Cytometric Bead Array	73
2.2.10	Illumina microarray hybridization.....	74
3	Characterization of the interaction of <i>S. flexneri</i> and <i>S. Typhimurium</i> with undifferentiated murine embryonic stem cells.....	75
3.1	Introduction.....	75
3.1.1	<i>Salmonella</i> interaction with <i>in vitro</i> models	75
3.2	Results.....	79
3.2.1	The interaction of <i>Shigella flexneri</i> with murine ES cells.....	79
3.2.1.1	The ability of <i>S. flexneri</i> Sh42 to invade Hep2 cells	79
3.2.1.2	Flow Cytometric characterization of AB2.2 murine ES cells	82
3.2.1.3	Gentamicin assay on AB2.2 mouse ES cells exposed to <i>S. flexneri</i> ...	84
3.2.1.4	Gentamicin assay using wild type <i>S. flexneri</i> M90TS and AB2.2 mouse ES cells	85
3.2.1.5	Flow cytometric analysis of AB2.2 infected by <i>S. flexneri</i>	86
3.2.1.6	Confocal imaging of AB2.2 murine ES cells infected by <i>S. flexneri</i> .	87
3.2.2	The interaction of <i>S. Typhimurium</i> with murine ES cells	91
3.2.2.1	Gentamicin assay of <i>S. Typhimurium</i> interaction with control J774A.1 cells	91
3.2.2.2	Flow cytometric analysis of <i>S. Typhimurium</i> infecting mouse J774A.1 cell line	92
3.2.2.3	Gentamicin assay monitoring the interaction of <i>S. Typhimurium</i> SL1344(p1C/1) with AB2.2 murine ES cells	93
3.2.2.4	Flow cytometric analysis of mouse ES cells infected with <i>S. Typhimurium</i> using a time course of infection.....	94

3.2.2.5 Confocal imaging of <i>S. Typhimurium</i> infecting AB2.2 murine ES cells	97
3.2.3 Role of Type III secretion systems during infection of mouse ES cells	100
3.2.3.1 Gentamicin assay using the <i>S. flexneri mxiD</i> mutant interacting with AB2.2 mouse ES cells	100
3.2.3.2 Gentamicin assay monitoring the levels of invasion of AB2.2 mouse ES cells by a <i>S. Typhimurium sipB</i> mutant	101
3.3 Discussion.....	102
4 Transcription profiling of murine ES cells infected by <i>S. Typhimurium</i> SL1344	108
4.1 Introduction.....	108
4.1.1 Microarrays in host-pathogen interactions studies	108
4.2 Experimental design	113
4.3 Results.....	114
4.3.1 Murine ES cell infection with <i>S. Typhimurium</i> and total RNA extraction	
114	
4.3.2 Murine ES cell total RNA extraction and analysis	116
4.3.3 cRNA synthesis, labelling and microarray hybridization.....	118
4.3.4 Microarray data analysis.....	120
4.3.4.1 Bioconductor analysis.....	120
4.3.4.1.1 Results from Bioconductor pair-comparison analysis	120
4.3.4.1.2 InnateDB pathways analysis	124
4.3.4.1.3 Real time RT-RCR to confirm Bioconductor analysis	127
4.3.4.1.4 Statistical analysis of RT-PCR data on genes identified by Bioconductor.....	128
4.3.4.2 GeneSpring analysis	130
4.3.4.2.1 Results from GeneSpring pair-comparison analysis.....	130
4.3.4.2.2	136
4.3.4.2.3 Gene Ontology analysis of the genes differentially expressed at 4h	
136	
4.3.4.2.4 Real time RT-PCR to confirm GeneSpring analysis	139
4.3.4.2.5 Statistical analysis of RT-PCR data on genes identified by GeneSpring	140
4.3.4.3 GEPAS: ASCA analysis	141
4.3.4.3.1 Time course analysis using ASCA	141

4.3.4.3.2 Functional category analysis using FatiGO on ASCA results....	148
4.3.4.3.3 Real Time RT-PCR relative quantification on genes derived from ASCA analysis.....	150
4.3.4.3.4 Statistical analysis of RT-PCR data on genes identified by ASCA	
151	
4.4 Discussion.....	152
5 Procedures for differentiating mouse Embryonic Stem cells into dendritic cell ..	159
5.1 Introduction.....	159
5.1.1 Stem cells and <i>in vitro</i> differentiation.....	159
5.1.2 Dendritic cells and their <i>ex-vivo</i> extraction and research application ..	161
5.2 Results.....	163
5.2.1 Formation of embryoid bodies and differentiation into dendritic cells	163
5.2.2 EsDC characterization by flow cytometric analysis	167
5.2.3 Confocal characterization esDCs.....	170
5.2.4 Confocal investigation of esDCs infected with <i>S. Typhimurium</i> SL1344	
174	
5.2.5 Electron microscopy characterization of esDCs.....	179
5.2.6 Functional assays on esDCs.....	181
5.2.6.1 Cytokine production by esDCs	181
5.2.6.2 Antigen presentation assay	183
5.3 Discussion.....	184
6 Messenger RNA expression profile analysis of <i>S. Typhimurium</i> infected esDCs	190
6.1 Introduction.....	190
6.1.1 <i>Salmonella</i> -DC interactions.....	190
6.1.2 Microarray analysis on DCs	191
6.2 Experimental design	194
6.3 Results.....	195
6.3.1 Infection of esDCs by <i>S. Typhimurium</i> SL1344	195
6.3.2 FACS sorting of esDCs infected with <i>S. Typhimurium</i> (p1C/1).....	196
6.3.3 Total RNA extraction, quantification and quality assessment.....	197
6.3.4 cRNA synthesis, labeling and hybridization on Illumina arrays	199
6.3.5 Bioconductor analysis and pathway analysis with InnateDB	199
6.3.6 Real time RT-PCR data on genes differentially expressed by esDCs	
during infection.....	204

6.3.7 Statistical analysis of the RT-PCR data on genes differentially expressed by esDCs during infection	205
6.4 Discussion.....	207
7 Final remarks and future work.....	213
8 Appendix A.....	218
8.1 Affymetrix QC report for Bioconductor analysis	218
8.2 Gene Ontology analysis of the top GeneSpring annotated genes.....	220
8.2.1 GO description for cellular component of the top genes deriving from GeneSpring analysis	220
8.2.2 GO description for biological process of the top genes deriving from GeneSpring analysis	221
8.3 Genes analyzed by RT-PCR deriving from ASCA analysis.....	223
9 Appendix B	224
9.1 Flow cytometric characterization of murine ES cells AB2.2, esDCs and BMDCs testing the expression of myeloid surface markers.....	224

Figures list

Figure 1.1	<i>Shigella</i> invasion of the gut mucosa	30
Figure 1.2	<i>Salmonella</i> invasion of the gut mucosa	36
Figure 1.3	Genetic manipulation of ES cells and their potential application.....	40
Figure 1.4	Generation of target mutant ES cells	42
Figure 1.5	TLRs and their respective binding products	45
Figure 1.6	TLR induced signaling pathways	46
Figure 1.7	Antigen processing and presentation trafficking inside DCs.....	48
Figure 3.1	Bacterial CFUs from gentamicin assay on Hep2 cells with <i>S. flexneri</i> Sh42 at MOI 100.....	80
Figure 3.2	Bacterial CFU counts at 2 and 4h infection of Hep2 with <i>S. flexneri</i> Sh42 harbouring the plasmid pJKD18 (Sh42/18)	81
Figure 3.3	Flow cytometric characterization of AB2.2 murine ES cells	83
Figure 3.4	CFU counts from gentamicin assays performed on AB2.2 with <i>Shigella flexneri</i> Sh42 with and without plasmid pJKD18 at MOI 10 and 100	84
Figure 3.5	CFU counts obtained during a gentamicin assay performed on mouse ES cells AB2.2 using wild type <i>S. flexneri</i> M90TS at MOI 100.....	85
Figure 3.6	Flow cytometric analysis of murine ES AB2.2 cells during infection with <i>S. flexneri</i> Sh42(pJKD18)	86
Figure 3.7	Confocal image of AB2.2 murine ES cells infected with <i>S. flexneri</i> Sh42 (pJKD18) at time point 0	87
Figure 3.8	Confocal image of AB2.2 murine ES cells after 30 minutes infection with <i>S. flexneri</i> Sh42(pJKD18).....	88
Figure 3.9	Confocal image of AB2.2 murine ES cells at 2h infection with <i>S. flexneri</i> Sh42(pJKD18)	89
Figure 3.10	Confocal image of AB2.2 murine ES cells at 2h infection with <i>S. flexneri</i> Sh42(pJKD18)	90
Figure 3.11	Gentamicin assay on mouse J774A.1 cells infected with <i>S. Typhimurium</i> SL1344	91
Figure 3.12	Flow cytometric analysis of murine J774A.1 cells infected with <i>S. Typhimurium</i> SL1344(p1C/1)	92

Figure 3.13 Gentamicin assay of mouse ES cells infected by <i>S. Typhimurium</i> SL1344 with or without the reporter plasmid p1C/1	93
Figure 3.14 Flow cytometric analysis of time course infection of mouse ES cells infected with <i>S. Typhimurium</i> expressing GFP protein	95
Figure 3.15 CFU counts from time course gentamicin assay of <i>S. Typhimurium</i> SL1344 infection of mouse ES cells.....	96
Figure 3.16 Confocal image of AB2.2 cells infected with <i>S. Typhimurium</i> at 30 minutes	97
Figure 3.17 Confocal image of AB2.2 mouse ES cells infected with <i>S. Typhimurium</i> (p1C/1) at 1 h.....	98
Figure 3.18 Confocal image of AB2.2 mouse ES cells infected with <i>S. Typhimurium</i> (p1C/1) at 1 h.....	99
Figure 3.19 Gentamicin assay performed on mouse ES cells using <i>S. flexneri</i> <i>mxiD</i> ⁻	100
Figure 3.20 Levels of <i>S. Typhimurium</i> SL1344 sipB mutant invasion of mouse ES cells AB2.2	101
Figure 4.1 Host-pathogen interactions that can be exploited using microarray technology	112
Figure 4.2 Flow cytometric analysis of murine ES cells infected with <i>S. Typhimurium</i> SL1344.....	115
Figure 4.3 Bioanalyzer analysis of total RNA from infected and uninfected ES cells	117
Figure 4.4 Bioanalyzer analysis of the biotin-labelled cRNA	118
Figure 4.5 RT-PCR results conducted on representative genes identified by the Bioconductor analysis of genes differentially expressed at 4h infection vs. uninfected cells	128
Figure 4.6 Whisker box plot of the RT-PCR results for the Bioconductor-generated differentially expressed genes.....	129
Figure 4.7 Graphical representation of the Gene Ontology analysis for molecular function of genes differentially expressed at 4h	138
Figure 4.8 RT-PCR results conducted on a few genes identified by GeneSpring analysis	139
Figure 5.1 Image of a cystic EB	164
Figure 5.2 Images of esDCs emerging during differentiation from EBs	165

Figure 5.3	Scheme of the differentiation protocol for transforming murine ES cells into esDCs	166
Figure 5.4	Images of immature esDC stained for the expression of MHC class II	171
Figure 5.5	Confocal image of murine esDC after over night activation with TNF α and stained for MHC II	172
Figure 5.6	Confocal images of esDC incubated with DQ OVA	173
Figure 5.7	Confocal image of esDC infected with <i>S. Typhimurium</i> SL1344 (p1C/1)	175
Figure 5.8	Confocal image of esDC incubated for 3h with <i>S. Typhimurium</i> SL1344 (p1C/1)	176
Figure 5.9	Confocal image of esDCs infected with <i>S. Typhimurium</i> SL1344 (p1C/1)	177
Figure 5.10	Transmission electron microscopic images of undifferentiated murine ES cells AB2.2 and derived esDC during infection with <i>S. Typhimurium</i> SL1344	180
Figure 6.1	FACS analysis of esDCs infected with <i>S. Typhimurium</i> SL1344(p1C/1)	195
Figure 6.2	EsDCs were infected with <i>S. Typhimurium</i> SL1344(p1C/1) and FACS sorted for transcriptome analysis	196
Figure 6.3	Bioanalyzer profile of the total RNA quality extracted from esDCs uninfected and infected with <i>S. Typhimurium</i> SL1344(p1C/1) at 2h and 4h	198
Figure 6.4	Graphical representation of qRT-PCR results	205
Figure 6.5	Whisker-Box plots for RT-PCR results statistical analysis	206
Figure 6.6	This Cytoscape picture represents the IL-12-mediated pathway at 4h.	209
Figure 6.7	Cytoscape representation of the SOCS pathway in esDCs at 4h infection	210
Figure 8.1	Affymetrix QC report	219
Figure 8.2	Pie chart of the GeneSpring data analyzed for GO term Cellular components	221
Figure 9.1	Flow cytometry characterization of murine AB2.2 ES cells	224
Figure 9.2	Murine ES cells characterization for myeloid markers	225
Figure 9.3	Flow cytometric characterization of immature and mature esDCs.....	226
Figure 9.4	Flow cytometric characterization of immature and mature esDCs, number 2	227
Figure 9.5	Flow cytometric characterization of BMDCs immature and mature....	228

Figure 9.6 Flow cytometric characterization of immature and mature BMDCs,
number 2 229

Tables list

Table 2.1	Antibodies for FACS analysis of murine ES and esDC characterization ...	59
Table 2.2	Isotype control antibodies for FACS analysis	59
Table 2.3	Antibodies used for confocal analysis	60
Table 2.4	RT-PCR Primers to confirm microarray data from murine ES cells uninfected and infected	61
Table 2.5	RT-PCR Primers to confirm microarray data from esDC uninfected and infected	62
Table 4.1	Total RNA concentration of murine ES cells infected by <i>S. Typhimurium</i> (p1C/1) measured with NanoDrop1000 technology.....	116
Table 4.2	Bioconductor analysis of RNA expression profile of murine ES cells at 2h infection	120
Table 4.3	Bioconductor analysis of RNA expression profile of murine ES cells at 4h infection	121
Table 4.4	Bioconductor analysis of RNA expression profile of murine ES cells at 4h infection compared to 2h	122
Table 4.5	InnateDB analysis of genes expressed by murine ES cells at 2h infection with <i>S. Typhimurium</i>	124
Table 4.6	InnateDB pathway analysis of murine ES cells expression profile at 4h infection: up-regulated pathways.....	125
Table 4.7	InnateDB pathway analysis of murine ES cells expression profile at 4h infection: down-regulated pathways.....	125
Table 4.8	InnateDB analysis of genes expressed by murine ES cells at 4h infection with <i>S. Typhimurium</i> compared to 2h: up-regulated pathways.....	126
Table 4.9	InnateDB analysis of genes expressed by murine ES cells at 4h infection with <i>S. Typhimurium</i> compared to 2h: down-regulated pathways.....	126
Table 4.10	GeneSpring analysis of the mRNA expression profile of AB2.2 murine ES cells at 2h infection	131
Table 4.11	GeneSpring analysis of the mRNA expression profile of AB2.2 murine ES cells at 4h infection	132
Table 4.12	GeneSpring analysis of the mRNA expression profile of AB2.2 murine ES cells at 4h vs. 2h infection.....	134

Table 4.13 Gene Ontology results in the molecular-function category for GeneSpring analysis	137
Table 4.14 Gene list derived from ASCA analysis of the genes up-regulated during infection	143
Table 4.15 Gene list derived from ASCA analysis of genes down-regulated during infection	145
Table 4.16 FatiGO analysis of up-regulated genes from ASCA analysis.....	148
Table 4.17 FatiGO analysis of down-regulated genes from ASCA analysis.....	149
Table 5.1 Flow cytometric analysis of surface markers of AB2.2 murine ES cells, esDC and BMDC, immature and matured with LPS, OVA and TNF α	169
Table 5.2 The levels in pg/ml of cytokines produced by AB2.2 murine ES cells and esDCs infected and uninfected with <i>S. Typhimurium</i> SL1344.	181
Table 5.3 Cytokine production by esDCs and BMDCs activated with <i>S. Typhimurium</i> LPS 10 μ g/ml, OVA protein 10 μ g/ml or TNF α 5000 WHOSU/ml.....	182
Table 5.4 Cytokine production by esDCs and BMDCs during antigen presentation assay	182
Table 5.5 IL-2 production by T cells activated during antigen presentation assays involving BMDCs and esDCs.....	183
Table 6.1 Total RNA concentration from esDC uninfected and infected with <i>S. Typhimurium</i> SL1344(p1C/1)	197
Table 8.1 GeneSpring data analyzed for GO term Cellular component.....	220
Table 8.2 GeneSpring pear-comparison data analyzed for GO term Biological Process	221
Table 8.3 Table Gene resulting from ASCA analysis which expression was confirmed by RT-PCR	223

Abbreviations

Ab : Antibody

Ag : Antigen

APC: Antigen Presentation Cell

Amp: Ampicillin

BM: Bone Marrow

BMDC: Bone Marrow derived Dendritic Cells

BSA : Bovine Serum Albumin

CBA: Cytometric Bead Array

CD: Cluster of Differentiation

ConA: Concanavalin A

Ct: Threshold Cycle

DC: Dendritic Cell

DMEM: Dulbecco's Modified Eagle's Medium

ECACC: European Collection of Cell Cultures

ES: Embryonic Stem

esDC: Embryonic stem cells derived Dendritic cell

FCS : Fetal Calf/Bovine Serum

FITC: Fluorescein isothiocyanate

GFP: Green Fluorescent Protein

GM-CSF : Granulocyte/Macrophage-Colony Stimulating Factor

HI-FBS: Heat Inactivated Foetal Bovine Serum

IL: Interleukin

IMDM: Iscove's modified Dulbecco's Medium

M&M: Materials and Methods

LB: Luria Bertani

LIF : Leukemia Inhibitory Factor

LPS: Lipopolysaccharide

MHC: Major Histocompatibility Complex

MOI: Multiplicity of Infection

OD: Optical Density

OVA : Ovalbumin

PAMP: Pathogen-Associated Molecular Pattern

PRR: Pattern Recognition Receptor

PBS: Phosphate Buffered Saline

PE: Phycoerythrin

QC: Quality Control

RT: Room Temperature

RT-PCR: Real Time Polymerase Chain Reaction

S. Typhimurium: *Salmonella enterica* serovar Typhimurium

SPI: Salmonella Pathogenic Island

TIIISS: Type Three Secretion System

TLR: Toll Like Receptor

TNF α : Tumor Necrosis Factor alpha

WTSI : Wellcome Trust Sanger Institute

WHOSU: World Health Organization Standard Units